Medroxyprogesterone acetate
- Generic Name
- Medroxyprogesterone acetate
- Brand Names
- Depo-provera, Depo-subq Provera, Premphase 28 Day, Prempro 0.625/2.5 28 Day, Provera
- Drug Type
- Small Molecule
- Chemical Formula
- C24H34O4
- CAS Number
- 71-58-9
- Unique Ingredient Identifier
- C2QI4IOI2G
- Background
Medroxyprogesterone acetate (MPA) is a progesterone derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prevent pregnancy, manage pain in endometriosi...
- Indication
Medroxyprogesterone acetate (MPA) oral tablets are indicated to treat secondary amenorrhea, reduce the incidence of endometrial hyperplasia in postmenopausal women, and to treat abnormal uterine bleeding due to hormonal imbalance, not organic pathology. Oral tablets containing MPA and conjugated estrogens are indicated to prevent postmenopausal osteoporosis ...
- Associated Conditions
- Abnormal Uterine Bleeding, Amenorrhea, Endometrial Hyperplasia, Endometriosis related pain, Metastatic Renal Cell Carcinoma ( mRCC), Osteoporosis, Pain, Postmenopausal Osteoporosis, Pregnancy, Vasomotor Symptoms Associated With Menopause, Vulvo Vaginal Atrophy, Metastatic Endometrial carcinoma
- Associated Therapies
- Contraception, Estrogen Replacement Therapy, Hormonal Contraception therapy
A Study of TCD601 in de Novo Renal Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2022-12-30
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- ITB-Med LLC
- Target Recruit Count
- 90
- Registration Number
- NCT05669001
- Locations
- 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
🇺🇸University of Cincinnati Medical Center, Cincinnati, Ohio, United States
🇺🇸University of California San Francisco Medical Center, San Francisco, California, United States
Risk Evaluation and Screening to Tailor Prevention and Reduce the Incidence of Endometrial Cancer
- First Posted Date
- 2022-12-15
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 250
- Registration Number
- NCT05651282
- Locations
- 🇨🇦
VGH Research Pavilion, Vancouver, British Columbia, Canada
Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Women With PCOS Undergoing PGT-A
- Conditions
- Interventions
- First Posted Date
- 2022-04-13
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- ShangHai Ji Ai Genetics & IVF Institute
- Target Recruit Count
- 204
- Registration Number
- NCT05326087
Refining Adjuvant Treatment in Endometrial Cancer Based on Molecular Features
- First Posted Date
- 2022-02-24
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Leiden University Medical Center
- Target Recruit Count
- 1615
- Registration Number
- NCT05255653
- Locations
- 🇨🇦
The POLEmut-BLUE trial: Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
🇳🇱Medisch Spectrum Twente, Enschede, Netherlands
🇳🇱The MMRd-GREEN trial: Leiden University Medical Center, Leiden, Netherlands
A Study to Evaluate the Pharmacokinetics (PK) of Medroxyprogesterone Acetate Following an Injection of TV-46046 in Healthy Women of Reproductive Age
- First Posted Date
- 2020-12-23
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT04682353
- Locations
- 🇺🇸
Teva Investigational Site 14002, Cypress, California, United States
🇺🇸Teva Investigational Site 14003, San Antonio, Texas, United States
🇩🇴Teva Investigational Site 18001, Santo Domingo, Dominican Republic
The Rate of Embryo Euploidy in Progestin-primed Ovarian Stimulation Cycles
- Conditions
- Interventions
- First Posted Date
- 2020-12-04
- Last Posted Date
- 2020-12-04
- Lead Sponsor
- Casa di Cura Privata Villa Mafalda
- Target Recruit Count
- 396
- Registration Number
- NCT04654741
- Locations
- 🇮🇹
Villa Mafalda, Roma, Italy
MPA Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia
- Conditions
- Interventions
- First Posted Date
- 2018-09-18
- Last Posted Date
- 2023-02-17
- Lead Sponsor
- Xiaojun Chen
- Target Recruit Count
- 471
- Registration Number
- NCT03675139
- Locations
- 🇨🇳
Obstetrics and Gynecology Hospital, Fudan University, Shanghai, Shanghai, China
Modifiers of Tenofovir in the Female Genital Tract
- Conditions
- Interventions
- First Posted Date
- 2017-12-19
- Last Posted Date
- 2018-05-01
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 50
- Registration Number
- NCT03377608
- Locations
- 🇺🇬
MU-JHU Care Ltd, Kampala, Uganda
Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-01-12
- Last Posted Date
- 2021-11-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT03018249
- Locations
- 🇺🇸
The Mark H Zangmeister Center, Columbus, Ohio, United States
🇺🇸UPMC-Saint Clair Hospital Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸John Muir Medical Center-Concord Campus, Concord, California, United States
Apoptotic Signaling Pathways in Rats With Endometrial Hyperplasia
- Conditions
- Interventions
- First Posted Date
- 2016-08-19
- Last Posted Date
- 2016-08-23
- Lead Sponsor
- Kayseri Education and Research Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT02872818
- Locations
- 🇹🇷
Kayseri Training and Research Hospital, Kayseri, Turkey
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.